Xenon Pharmaceuticals (XENE) Retained Earnings (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Retained Earnings of -$1.2 million for Q1 2026, down 44.86% year-over-year from -$2.2 million in Q1 2025, and down 461.49% quarter-over-quarter from $335000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Retained Earnings (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Retained Earnings for 14 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 44.86% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$1.2 million (down 44.86% YoY), while the FY2025 annual figure was $335000.0, up 100.04% from the prior year.
- Retained Earnings fell to -$1.2 million in Q1 2026 per XENE's latest filing, from $335000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $335000.0 in Q4 2025 and bottomed at -$1.1 billion in Q3 2025.
- Historically, Retained Earnings has averaged -$461.0 million across 5 years, with a median of -$482.7 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 48662.32% — and 2025, when it surged 100.04%.
- Xenon Pharmaceuticals' Retained Earnings stood at -$482.7 million in 2022, then slumped by 37.78% to -$665.1 million in 2023, then plunged by 35.23% to -$899.5 million in 2024, then soared by 100.04% to $335000.0 in 2025, then plunged by 461.49% to -$1.2 million in 2026.
- Business Quant data shows XENE's Retained Earnings at -$1.2 million in Q1 2026, $335000.0 in Q4 2025, and -$1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -1.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.46 Bn |
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | 335,000.00 |
| Sep 30, 2025 | -1.14 Bn |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | -836,000.00 |
| Dec 31, 2024 | -899.47 Mn |
| Sep 30, 2024 | -833.79 Mn |
| Jun 30, 2024 | -771.00 Mn |
| Mar 31, 2024 | -713.07 Mn |
| Dec 31, 2023 | -665.14 Mn |
| Sep 30, 2023 | -2.95 Mn |
| Jun 30, 2023 | -571.94 Mn |
| Mar 31, 2023 | -524.47 Mn |
| Dec 31, 2022 | -482.75 Mn |
| Sep 30, 2022 | -445.35 Mn |
| Jun 30, 2022 | -408.20 Mn |
| Mar 31, 2022 | -377.04 Mn |
| Dec 31, 2021 | -990,000.00 |
| Sep 30, 2021 | -331.81 Mn |